238 related articles for article (PubMed ID: 19968833)
41. Hormonal changes induced by bromocriptine (CB-154) at the early stage of treatment.
Strauch G; Valcke JC; Mahoudeau JA; Bricaire H
J Clin Endocrinol Metab; 1977 Mar; 44(3):588-90. PubMed ID: 576425
[TBL] [Abstract][Full Text] [Related]
42. A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia.
Lamberts SW; Quik RF
J Clin Endocrinol Metab; 1991 Mar; 72(3):635-41. PubMed ID: 1997518
[TBL] [Abstract][Full Text] [Related]
43. [Clinical study on effect of Bushen Tiaogan Lianru recipe on hyperprolactinemia].
Liu J; Wang J; Chen X
Zhongguo Zhong Xi Yi Jie He Za Zhi; 1998 Mar; 18(3):142-4. PubMed ID: 11367660
[TBL] [Abstract][Full Text] [Related]
44. [Hyperprolactinemic amenorrhea:treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study].
Pascal-Vigneron V; Weryha G; Bosc M; Leclere J
Presse Med; 1995 Apr; 24(16):753-7. PubMed ID: 7784413
[TBL] [Abstract][Full Text] [Related]
45. Bone density and reproductive hormones in patients with neuroleptic-induced hyperprolactinemia.
Ataya K; Mercado A; Kartaginer J; Abbasi A; Moghissi KS
Fertil Steril; 1988 Dec; 50(6):876-81. PubMed ID: 2904890
[TBL] [Abstract][Full Text] [Related]
46. Hyperprolactinemia presenting with encephalomalacia-associated seizure disorder and infertility: a novel application for bromocriptine therapy in reproductive endocrinology.
Saie DJ; Sills ES
Neuro Endocrinol Lett; 2005 Oct; 26(5):533-5. PubMed ID: 16264405
[TBL] [Abstract][Full Text] [Related]
47. Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia?
O'Keane V; Meaney AM
J Clin Psychopharmacol; 2005 Feb; 25(1):26-31. PubMed ID: 15643097
[TBL] [Abstract][Full Text] [Related]
48. Pergolide and bromocriptine for the treatment of patients with hyperprolactinemia.
Kletzky OA; Borenstein R; Mileikowsky GN
Am J Obstet Gynecol; 1986 Feb; 154(2):431-5. PubMed ID: 3080892
[TBL] [Abstract][Full Text] [Related]
49. Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders.
Tollin SR
J Endocrinol Invest; 2000 Dec; 23(11):765-70. PubMed ID: 11194712
[TBL] [Abstract][Full Text] [Related]
50. Hyperprolactinemia with prolonged amenorrhea reversed with bromocriptine in a menopausal woman.
Goldman M; Steinberger A; Ganti S
Am J Obstet Gynecol; 1988 Jan; 158(1):117-8. PubMed ID: 3122579
[TBL] [Abstract][Full Text] [Related]
51. Peony-Glycyrrhiza Decoction for Antipsychotic-Related Hyperprolactinemia in Women With Schizophrenia: A Randomized Controlled Trial.
Man SC; Li XB; Wang HH; Yuan HN; Wang HN; Zhang RG; Tan QR; Wong HK; McAlonan GM; Wang CY; Zhang ZJ
J Clin Psychopharmacol; 2016 Dec; 36(6):572-579. PubMed ID: 27755159
[TBL] [Abstract][Full Text] [Related]
52. Antipsychotic-induced hyperprolactinaemia.
Inder WJ; Castle D
Aust N Z J Psychiatry; 2011 Oct; 45(10):830-7. PubMed ID: 21714721
[TBL] [Abstract][Full Text] [Related]
53. The effect of two dopaminergic drugs on menstrual function and psychological state in hyperprolactinemia.
Lappöhn RE; van de Wiel HB; Brownell J
Fertil Steril; 1992 Aug; 58(2):321-7. PubMed ID: 1353028
[TBL] [Abstract][Full Text] [Related]
54. Comparing the Effectiveness and Safety of the Addition of and Switching to Aripiprazole for Resolving Antipsychotic-Induced Hyperprolactinemia: A Multicenter, Open-Label, Prospective Study.
Yoon HW; Lee JS; Park SJ; Lee SK; Choi WJ; Kim TY; Hong CH; Seok JH; Park IH; Son SJ; Roh D; Kim BR; Lee BO
Clin Neuropharmacol; 2016; 39(6):288-294. PubMed ID: 27438182
[TBL] [Abstract][Full Text] [Related]
55. Extrapyramidal Symptoms During Risperidone Maintenance Treatment in Schizophrenia: A Prospective, Multicenter Study.
Bo QJ; Li XB; Wang ZM; Li AN; Ma X; Wang CY
J Clin Psychopharmacol; 2016 Apr; 36(2):125-9. PubMed ID: 26848792
[TBL] [Abstract][Full Text] [Related]
56. [Hyperprolactinemia and pregnancy].
Ionescu O; Vulpoi C; Cristea C; Ionescu D; Zbranca E
Rev Med Chir Soc Med Nat Iasi; 2002; 106(1):60-4. PubMed ID: 12635361
[TBL] [Abstract][Full Text] [Related]
57. Acute and long-term effects of once-daily oral bromocriptine and a new long-acting non-ergot dopamine agonist, quinagolide, in the treatment of hyperprolactinemia: a double-blind study.
Verhelst JA; Froud AL; Touzel R; Wass JA; Besser GM; Grossman AB
Acta Endocrinol (Copenh); 1991 Oct; 125(4):385-91. PubMed ID: 1683503
[TBL] [Abstract][Full Text] [Related]
58. Effectiveness of vaginal bromocriptine in treating women with hyperprolactinemia.
Kletzky OA; Vermesh M
Fertil Steril; 1989 Feb; 51(2):269-72. PubMed ID: 2912773
[TBL] [Abstract][Full Text] [Related]
59. BMY 14802, a sigma receptor ligand for the treatment of schizophrenia.
Gewirtz GR; Gorman JM; Volavka J; Macaluso J; Gribkoff G; Taylor DP; Borison R
Neuropsychopharmacology; 1994 Feb; 10(1):37-40. PubMed ID: 7910021
[TBL] [Abstract][Full Text] [Related]
60. Adjunctive metformin for antipsychotic-related hyperprolactinemia: A meta-analysis of randomized controlled trials.
Zheng W; Yang XH; Cai DB; Ungvari GS; Ng CH; Wang N; Ning YP; Xiang YT
J Psychopharmacol; 2017 May; 31(5):625-631. PubMed ID: 28372526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
